Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.58 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | FASN | P49327 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076830 | 0.94 | CA12 (0.65) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6350965 | 0.92 | CA12 (0.71) | CA12CA1CA2CA9CA14 | |
| Hydrogen Sulfide SCHEMBL27727970 | 0.90 | CA12 (0.53) | CA12CA1CA2CA9CA14 | |
| SCHEMBL28719728 | 0.88 | TSHR (0.60) | CA12CA1CA2CA9CA14 | |
| Hydrogen Peroxide SCHEMBL28425777 | 0.88 | TDP1 (0.64) | CA12CA1CA2CA9CA14 | |
| SCHEMBL260960 | 0.88 | TDP1 (0.64) | CA12CA1CA2CA9CA14 | |
| SCHEMBL29199324 | 0.88 | TDP1 (0.64) | CA12CA1CA2CA9CA14 | |
| Hydrogen Peroxide SCHEMBL28474133 | 0.88 | TDP1 (0.64) | CA12CA1CA2CA9CA14 | |
| Hydrochloric Acid SCHEMBL23276979 | 0.86 | TDP1 (0.62) | CA12CA1CA2CA9CA14 | |
| SCHEMBL19895794 | 0.86 | TDP1 (0.62) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040076905-A1 | Onium salts and positive resist materials using the same | YAGIHASHI FUJIO (JP) | 2004-04-22 | — | — | US | claimed |
| US-20030096189-A1 | ONIUM SALTS AND POSITIVE RESIST MATERIALS USING THE SAME | YAGIHASHI FUJIO (JP) | 2003-05-22 | — | — | US | claimed |
| EP-0615163-B1 | Positive resist material using particular onium salts | SHINETSU CHEMICAL CO (JP) | 1999-12-29 | — | — | EP | claimed |
| EP-0615163-A1 | Onium salts and positive resist materials using the same | Shin-Etsu Chemical Co., Ltd. (JP) | 1994-09-14 | — | — | EP | claimed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| CN-115141072-A | Preparation method of biphenyl and derivatives thereof | 江苏师范大学 | 2022-10-04 | — | — | CN | disclosed |
| CN-115087658-A | Sulfonamide or sulfenamide compounds having BRD 4-inducing proteolytic activity, and pharmaceutical use thereof | 田边三菱制药株式会社 | 2022-09-20 | — | — | CN | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-6841334-B2 | Onium salts and positive resist materials using the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2005-01-11 | — | — | US | disclosed |
| US-20040076905-A1 | Onium salts and positive resist materials using the same | YAGIHASHI FUJIO (JP) | 2004-04-22 | — | — | US | disclosed |
| US-6667415-B1 | Dissolution inhibitors; sensitivity, resolution, process-ability; preservation stability | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
| US-20030096189-A1 | ONIUM SALTS AND POSITIVE RESIST MATERIALS USING THE SAME | YAGIHASHI FUJIO (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-0615163-B1 | Positive resist material using particular onium salts | SHINETSU CHEMICAL CO (JP) | 1999-12-29 | — | — | EP | disclosed |
| EP-0646568-B1 | Tertiary butyl 4,4-bis(4'-hydroxyphenyl) pentanoate derivatives and positive resist materials containing the same | SHINETSU CHEMICAL CO (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0646568-A2 | Tertiary butyl 4,4-bis(4'-hydroxyphenyl) pentanoate derivatives and positive resist materials containing the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1995-04-05 | — | — | EP | disclosed |
| EP-0615163-A1 | Onium salts and positive resist materials using the same | Shin-Etsu Chemical Co., Ltd. (JP) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CA12 247/4885CA1 804/4885CA2 2365/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | CA12 247/4885CA1 804/4885CA2 2365/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CA12 195/4885CA1 629/4885CA2 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.